SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Syncom Formulations (India) informs about standalone unaudited financial results

23 Dec 2017 Evaluate

Syncom Formulations (India) has informed about submission of Revised Standalone Unaudited Financial Results along with Limited Review Report thereon by Statutory Auditors for Quarter/ Half-Year ended on 30th September, 2017 in accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Syncom Formulations Share Price

13.55 -0.34 (-2.45%)
24-Apr-2026 10:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1625.00
Dr. Reddys Lab 1308.05
Cipla 1288.40
Zydus Lifesciences 925.60
Lupin 2307.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×